Show simple item record

dc.contributor.authorAvni, Bayraktar Fatih
dc.contributor.authorEmre, Selcuk
dc.contributor.authorArikan, Ali Ahmet
dc.date.accessioned2020-05-22T20:59:13Z
dc.date.available2020-05-22T20:59:13Z
dc.date.issued2019-10-01T00:00:00Z
dc.identifier.urihttps://hdl.handle.net/20.500.12645/18009
dc.description.abstractInferior vena cava agenesis is a rare anomaly which may result in deep vein thrombosis. There is no clear scientific evidence for the most effective therapeutic management, optimal duration, or the choice of anticoagulant therapy. Herein, we report an 18-year-old male case with deep vein thrombosis associated with inferior vena cava agenesis who was on rivaroxaban as a lifelong anticoagulation treatment for symptoms of venous stasis and the presence of heterozygotic thrombophilic mutations.
dc.language.isoen
dc.subjectArikan A. A. , Emre S., Avni B. F. , -The use of rivaroxaban in deep venous thrombosis associated with vena cava inferior agenesis-, TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.27, ss.583-585, 2019
dc.titleThe use of rivaroxaban in deep venous thrombosis associated with vena cava inferior agenesis
dc.typeArticle
dc.identifier.wosWOS:000492824600028
dc.identifier.scopus85074376735
dc.identifier.doi10.5606/tgkdc.dergisi.2019.17672
dc.identifier.pubmed
local.publication.isinternational1


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record